(NASDAQ: PCRX) Pacira Biosciences's forecast annual revenue growth rate of 15.88% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 11.53%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 8.77%.
Pacira Biosciences's revenue in 2023 is $666,823,000.On average, 4 Wall Street analysts forecast PCRX's revenue for 2023 to be $38,169,069,971, with the lowest PCRX revenue forecast at $36,811,358,884, and the highest PCRX revenue forecast at $41,840,165,250. On average, 4 Wall Street analysts forecast PCRX's revenue for 2024 to be $42,813,530,045, with the lowest PCRX revenue forecast at $40,684,461,132, and the highest PCRX revenue forecast at $46,279,171,920.
In 2025, PCRX is forecast to generate $47,724,835,997 in revenue, with the lowest revenue forecast at $43,861,705,430 and the highest revenue forecast at $52,283,778,561.